Spire Wealth Management Lowers Position in Cencora, Inc. $COR

Spire Wealth Management decreased its position in shares of Cencora, Inc. (NYSE:COR) by 70.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 1,789 shares of the company’s stock after selling 4,235 shares during the period. Spire Wealth Management’s holdings in Cencora were worth $559,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Baader Bank Aktiengesellschaft lifted its holdings in shares of Cencora by 318.5% during the second quarter. Baader Bank Aktiengesellschaft now owns 4,336 shares of the company’s stock valued at $1,300,000 after purchasing an additional 3,300 shares during the last quarter. Focus Partners Wealth increased its position in Cencora by 25.8% during the 1st quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after buying an additional 1,171 shares in the last quarter. Acadian Asset Management LLC raised its stake in Cencora by 947.5% during the second quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after buying an additional 232,539 shares during the last quarter. Martin Capital Partners LLC boosted its holdings in Cencora by 205.2% in the second quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock worth $1,135,000 after acquiring an additional 2,544 shares in the last quarter. Finally, Fiduciary Alliance LLC purchased a new stake in shares of Cencora in the second quarter worth $262,000. Institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Bank of America dropped their price target on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. TD Cowen lifted their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Wells Fargo & Company upped their target price on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Mizuho raised their price target on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Finally, UBS Group upped their price objective on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $379.50.

Cencora Trading Down 0.0%

Shares of COR stock opened at $335.73 on Friday. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a 12-month low of $233.61 and a 12-month high of $377.54. The stock has a market capitalization of $65.13 billion, a P/E ratio of 42.23, a P/E/G ratio of 1.60 and a beta of 0.66. The firm’s 50 day moving average is $349.89 and its 200 day moving average is $318.27.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the business earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were paid a dividend of $0.60 per share. The ex-dividend date was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is presently 30.19%.

Insider Activity

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the sale, the executive vice president owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This represents a 12.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the transaction, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. The trade was a 8.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 20,317 shares of company stock valued at $7,009,260 in the last quarter. 10.80% of the stock is currently owned by insiders.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.